参考文献/References:
[1] Franceschi E, Tosoni A, Bartolini S, et al. Treatment options
for recurrent glioblastoma: pitfalls and future trends [J].
Expert Rev Anticancer Ther, 2009, 9(5): 613-619.
[2] Chamberlain M. Evolving strategies: future treatment of
glioblastoma [J]. Expert Rev Neurother, 2014, 11(4): 519-
532.
[3] Pazdur R. Endpoints for assessing drug activity in clinical
trials [J]. Oncologist, 2008, 13 Suppl 2: 19-21.
[4] Franceschi E, Agati R, Brandes AA. End points for Phase
Ⅱ trials in recurrent glioblastoma: the cornerstone for a new
era [J]. Expert Rev Anticancer Ther, 2011, 11(11): 1713-
1717.
[5] Johansson F, Ekman S, Blomquist E, et al. A review of dose-
dense temozolomide alone and in combination with bevaci-
zumab in patients with first relapse of glioblastoma [J].
Anticancer Res, 2012, 32(9): 4001-4006.
[6] Kreisl T N, Kim L, Moore K, et al. Phase Ⅱ trial of single-
agent bevacizumab followed by bevacizumab plus irinotecan
at tumor progression in recurrent glioblastoma [J]. J Clin
Oncol, 2009, 27(5): 740-745.
[7] Vredenburgh JJ, Desjardins A, Herndon JN, et al. Bevaci-
zumab plus irinotecan in recurrent glioblastoma multiforme
[J]. Ann Oncol, 2013, 32(7): 2003-3006.
[8] Narayana A, Kelly P, Golfinos J, et al. Antiangiogenic
therapy using bevacizumab in recurrent high-grade glioma:
impact on local control and patient survival [J]. J Neuro-
surg, 2009, 110(1): 173-180.
[9] Poulsen H S, Grunnet K, Sorensen M, et al. Bevacizumab
plus irinotecan in the treatment patients with progressive
recurrent malignant brain tumours [J]. Acta Oncol, 2009,
48(1): 52-58.
[10] Cao Y, Tan A, Gao F, et al. A meta-analysis of randomized
controlled trials comparing chemotherapy plus bevacizumab
with chemotherapy alone in metastatic colorectal cancer [J].
Int J Colorectal Dis, 2009, 24(6): 677-685.
[11] Verhoeff J J, Lavini C, van Linde M E, et al. Bevacizumab
and dose-intense temozolomide in recurrent high-grade
glioma [J]. Ann Oncol, 2010, 21(8): 1723-1727.
[12] Gorski D H, Beckett MA, Jaskowiak NT, et al. Blockage of
the vascular endothelial growth factor stress response
increases the antitumor effects of ionizing radiation [J].
Cancer Res, 2014, 59(14): 3374-3378.
[13] Bao S, Wu Q, Mclendon RE, et al. Glioma stem cells
promote radioresistance by preferential activation of the
DNA damage response [J]. Nature, 2006, 444(7120): 756-
760.
[14] Gutin PH, Iwamoto FM, Beal K, et al. Safety and efficacy of
bevacizumab with hypofractionated stereotactic irradiation
for recurrent malignant gliomas [J]. Int J Radiat Oncol Biol
Phys, 2009, 75(1): 156-163.
[15] Bleeker F E, Molenaar R J, Leenstra S. Recent advances in
the molecular understanding of glioblastoma [J]. J Neuroon-
col, 2012, 108(1): 11-27.
[16] Quant EC, Norden AD, Drappatz J, et al. Role of a second
chemotherapy in recurrent malignant glioma patients who
progress on bevacizumab [J]. Neuro Oncol, 2009, 11(5):
550-555.
[17] Iwamoto FM, Abrey LE, Beal K, et al. Patterns of relapse
and prognosis after bevacizumab failure in recurrent glio-
blastoma [J]. Neurology, 2009, 73(15): 1200-1206.
[18] Chamberlain M C. Emerging clinical principles on the use of
bevacizumab for the treatment of malignant gliomas [J].
Cancer, 2010, 116(17): 3988-3999.
相似文献/References:
[1]闫 进 李 松 杨 辉.1H-MRS对卵泡刺激素免疫阳性垂体腺瘤的诊断和预后评估的价值[J].中国临床神经外科杂志,2015,(10):588.[doi:10.13798/j.issn.1009-153X.2015.10.004]
YAN Jin,LI Song,YANG Hui..Value of 1H-MRS to diagnosis and assessment of prognoses in patients with non-functioning gonadotroph adenomas[J].,2015,(10):588.[doi:10.13798/j.issn.1009-153X.2015.10.004]
[2]李继强 杨吉安 邵灵敏 吴庭枫 刘宝辉 陈谦学.稳定低表达BAG3的胶质母细胞瘤U87细胞株的构建及鉴定[J].中国临床神经外科杂志,2015,(06):353.[doi:10.13798/j.issn.1009-153X.2015.06.011]
LI Ji-qiang,YANG Ji-an,SHAO Ling-min,et al.Construction and identification of U87 glioblastoma cell strain with a stable low expression of BAG3[J].,2015,(10):353.[doi:10.13798/j.issn.1009-153X.2015.06.011]
[3]孙文栋 甘 宁 刘思思 李春晖.胶质肉瘤1例[J].中国临床神经外科杂志,2015,(06):356.[doi:10.13798/j.issn.1009-153X.2015.06.012]
[4]祝 斐 颉 奎 饶 敏 黄 新 吴 明 金卫星 朱炯明.良性脑膜瘤术后复发的影响因素分析[J].中国临床神经外科杂志,2015,(02):90.[doi:10.13798/j.issn.1009-153X.2015.02.008]
ZHU Fei,XIE Kui,RAO Min,et al.Analysis of factors related to postoperative recurrence of benign meningiomas[J].,2015,(10):90.[doi:10.13798/j.issn.1009-153X.2015.02.008]
[5]邓友寿.经蝶入路切除垂体腺瘤的疗效及复发影响因素分析[J].中国临床神经外科杂志,2016,(09):533.[doi:10.13798/j.issn.1009-153X.2016.09.008]
DENG You-shou..An analysis of curative effect of transsphenoidal surgery on pituitary adenomas and factors related to relapse in the patients with pituitary adenomas[J].,2016,(10):533.[doi:10.13798/j.issn.1009-153X.2016.09.008]
[6]李正伟、徐成仕、陈新军、李志强、江普查、陈劲草.夹闭术治疗栓塞后复发的颅内动脉瘤的疗效分析[J].中国临床神经外科杂志,2017,(08):542.[doi:10.13798/j.issn.1009-153X.2017.08.006]
LI Zheng-wei,XU Cheng-shi,CHEN Xin-jun,et al.Microsurgical management of recurrent intracranial aneurysms after embolization[J].,2017,(10):542.[doi:10.13798/j.issn.1009-153X.2017.08.006]
[7]孙文华 樊翊凌 丁圣豪 赵 兵 潘耀华 万杰清.亚急性、慢性椎-基底动脉闭塞的血管内再通治疗分析[J].中国临床神经外科杂志,2017,(08):545.[doi:10.13798/j.issn.1009-153X.2017.08.007]
SUN Wen-hua,FAN Yi-ling,DING Sheng-hao,et al.Curative effects of endovascular recanalization on subacute and chronic vertebrobasilar artery occlusion[J].,2017,(10):545.[doi:10.13798/j.issn.1009-153X.2017.08.007]
[8]桂志勇 冯 军 黄俊红 白敬洋.靶向沉默c-fos基因表达对胶质瘤U87MG细胞增殖与侵袭的影响[J].中国临床神经外科杂志,2017,(12):834.[doi:10.13798/j.issn.1009-153X.2017.12.011]
GUI Zhi-yong,FENG Jun,HUANG Jun-hong,et al.Effects of c-fos targeted silence on proliferation and invasiveness of human glioma cell U87[J].,2017,(10):834.[doi:10.13798/j.issn.1009-153X.2017.12.011]
[9]王娇燕 孟凡华 刘魏然 魏春晓 林丽萍.SWI在胶质母细胞瘤与单发脑转移瘤鉴别中的价值[J].中国临床神经外科杂志,2018,(01):13.[doi:10.13798/j.issn.1009-153X.2018.01.005]
WANG Jiao-yan,MENG Fan-hua,LIU Wei-ran,et al.Value of susceptibility-weighted imaging in differentiative diagnosis of glioblastomas and solitary brain metastases[J].,2018,(10):13.[doi:10.13798/j.issn.1009-153X.2018.01.005]
[10]张治元 王汉东 樊友武 贾 玥 吴晋蓉.胶质肉瘤15例分析及文献复习[J].中国临床神经外科杂志,2018,(02):69.
ZHANG Zhi-yuan,WANG Han-dong,FAN You-wu,et al.Diagnosis and treatment of gliosarcoma: a report of 15 cases and literature review[J].,2018,(10):69.
[11]谢宝树 张 林 王 宇 贾 锋 殷玉华.复发性多发胶质母细胞瘤的预后分析[J].中国临床神经外科杂志,2016,(06):333.[doi:10.13798/j.issn.1009-153X.2016.06.005]
XIE Bao-shu,ZHANG Lin,WANG Yu,et al.Analysis of prognoses in patients with recurrent multiple glioblastomas[J].,2016,(10):333.[doi:10.13798/j.issn.1009-153X.2016.06.005]